^

Health

Therapeutic hemapheresis

, medical expert
Last reviewed: 04.07.2025
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Therapeutic hemapheresis includes plasmapheresis and cytapheresis, which are usually tolerated in healthy donors. However, there are many minor and a few significant risks. The placement of venous catheters required for hemapheresis may cause complications (bleeding, infection, pneumothorax). Citrate anticoagulant may decrease serum ionized calcium. Plasma replacement with noncolloidal solutions (eg, saline) results in fluid shift to the extravascular space. Colloidal solutions do not replace IgG and sequestering factors.

Most complications can be controlled with close patient monitoring and adjustment of procedural parameters, but some severe reactions and isolated deaths have been reported.

Plasmapheresis

Therapeutic plasmapheresis removes plasma components from the blood. A blood cell separator removes the patient's plasma and returns red blood cells and platelets or plasma-substituting solutions; for this purpose, 5% albumin is preferred over fresh frozen plasma (except in patients with thrombotic thrombocytopenic purpura) because albumin causes fewer transfusion reactions and is not a vector for infection. Therapeutic plasmapheresis is similar to dialysis but can additionally remove protein-bound toxic substances. Exchange of one volume of plasma removes about 66% of such components.

To be effective, plasmapheresis must be used in diseases where the plasma contains known pathogenic substances and plasmapheresis can remove these substances faster than the body produces them. For example, in rapidly progressing autoimmune diseases, plasmapheresis can be used to remove harmful plasma components (e.g., cryoglobulins, antiglomerular antibodies), while immunosuppressive or cytotoxic drugs impair their production. There are numerous indications for plasmapheresis. The frequency of plasmapheresis, the volume of plasma removed, the type of replacement solution, and other parameters are individual. Low-density lipoprotein cholesterol can be removed by plasmapheresis using a recently proposed instrumental filtration method. Complications of plasmapheresis are similar to those of therapeutic cytapheresis.

Indications for plasmapheresis according to the American Society of Apheresis and Transfusion Medicine guidelines

Category

Plasmapheresis

Cytapheresis

I. Standard measures recommended in certain circumstances, including primary therapy

Acute inflammatory demyelinating polyradiculoneuropathy.

A disease caused by antiglomerular antibodies.

Chronic inflammatory demyelinating polyradiculoneuropathy. Demyelinating polyneuropathy with IgG/IgA.

Myasthenia gravis.

Phytanic acid storage disease.

Post-transfusion purpura.

Thrombotic
thrombocytopenic purpura

Cutaneous T-cell lymphoma: photopheresis.

Erythrocytosis/polycythemia vera.

Familial hypercholesterolemia: lipid absorption

Hyperleukocytosis: leukodepletion.

Sickle cell anemia: erythrocyte metabolism.

Thrombocytosis: platelet depletion

II. Recommendations with sufficient evidence of efficacy; acceptable as adjunctive treatment

ABO incompatible bone marrow transplant (recipient).

Acute inflammatory demyelinating
disease of the central nervous system.

Coagulation factor inhibitors.

Cryoglobulinemia.

Cryoglobulinemia
with polyneuropathy.

Familial hypercholesterolemia.

Eaton-Lambert syndrome.

Myeloma/acute renal failure.

Myeloma/paraproteins/hyperviscosity/PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections).

Polyneuropathy with IgM (+ Waldenstrom).

Rapidly progressive glomerulonephritis.

Chorea

Chronic graft-versus-host disease: photopheresis.

Erythrocytosis/polycythemia vera: depletion of red blood cells.

Hyperparasitemia - malaria.

Babesiosis: erythrocyte metabolism.

Idiopathic thrombocytopenic purpura: immunoadsorption.

RA: immunoadsorption

Cytapheresis

Therapeutic cytapheresis removes cellular components from the blood, returning the plasma. It is most often used to remove defective red blood cells and replace them with normal ones in patients with sickle cell anemia in the following conditions: acute coronary syndrome, stroke, pregnancy, frequent crises. Cytapheresis achieves a decrease in HbS levels to < 30% without the risk of increasing blood viscosity, which can occur with conventional transfusion. Therapeutic cytapheresis can be used to reduce severe thrombocytosis or leukocytosis (cytoreduction) in acute or chronic leukemia when there is a risk of bleeding, thrombosis, pulmonary or cerebral complications caused by high leukocytosis (leukostasis). Cytapheresis is especially effective in thrombocytosis, because platelets are not replaced as quickly as leukocytes. One or two procedures reduce the platelet level to a safe level. Therapeutic reduction of white blood cell count (leukapheresis) can remove kilograms of buffy coat in a small number of procedures, often reducing leukostasis and splenomegaly. However, the reduction in white blood cell count is only small and short-lived.

Another indication for the use of cytapheresis is the collection of peripheral blood stem cells for autologous or allogeneic transplantation, and the collected lymphocytes are used for immunomodulation in cancer therapy.

trusted-source[ 1 ], [ 2 ], [ 3 ]

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.